RT Journal Article
SR Electronic
T1 Genetics of the human microglia regulome refines Alzheimer’s disease risk loci
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.17.21264910
DO 10.1101/2021.10.17.21264910
A1 Kosoy, Roman
A1 Fullard, John F.
A1 Zeng, Biao
A1 Bendl, Jaroslav
A1 Dong, Pengfei
A1 Rahman, Samir
A1 Kleopoulos, Steven P.
A1 Shao, Zhiping
A1 Humphrey, Jack
A1 Lopes, Katia de Paiva
A1 Charney, Alexander W.
A1 Kopell, Brian. H.
A1 Raj, Towfique
A1 Bennett, David
A1 Kellner, Christopher P.
A1 Haroutunian, Vahram
A1 Hoffman, Gabriel E.
A1 Roussos, Panos
YR 2021
UL http://medrxiv.org/content/early/2021/10/18/2021.10.17.21264910.abstract
AB Microglia are brain resident myeloid cells that play a critical role in neuroimmunity and the etiology of Alzheimer’s Disease (AD). Yet our understanding of how the genetic regulatory landscape controls microglial function and contributes to disease is limited. Here, we performed transcriptome and chromatin accessibility profiling in primary human microglia from 150 donors to identify genetically-driven variation and cell-specific enhancer-promoter interactions. Integrative fine-mapping analysis identified putative regulatory mechanisms for 21 AD risk loci, of which 18 were refined to a single gene, including 3 novel genes (KCNN4, FIBP and LRRC25). Transcription factor regulatory networks captured AD risk variation and identified SPI1 as a key regulator of microglia expression and AD risk. This comprehensive resource capturing variation in the human microglia regulome provides novel insights into the etiology of neurodegenerative disease.One-Sentence Summary Characterizing the genetic regulation of chromatin accessibility and gene expression in human microglia refines molecular mechanisms of Alzheimer’s disease risk loci.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by the National Institute on Aging, NIH grants R01-AG050986 (to P.R.), R01-AG067025 (to P.R. and V.H.) and R01-AG065582 (to P.R. and V.H.). J.B. is partially supported by a NARSAD Young Investigator Grant 27209 from the Brain and Behavior Research Foundation (BBRF). P.D. is partially supported by a NARSAD Young Investigator Grant from the Brain and Behavior Research Foundation (BBRF).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Program for the Protection of Human Subjects Office (PPHS)/Icahn School of Medicine Institutional Review Board gave ethical approval for this work for samples from The Mount Sinai/JJ Peters VA Medical Center NIH Brain and Tissue Repository (NBTR), and from STUDY-13-00415 and STUDY-18-01012A projects. Institutional Review Board of Rush University Medical Center gave ethical approval for this work for samples from Rush University Medical Center/Rush Alzheimer Disease Center (RADC)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used for this analysis comes from the AMP-AD Knowledge Portal (https://adknowledgeportal.synapse.org/Explore/Studies/DetailsPage?Study=syn25671134) and is hosted on the Sage Bionetworks Synapse platform for access by qualified investigators. Data was generated from post-mortem tissue and has been de-identified according to the Synapse terms of use, and is available through the submission of a AD Knowledge Portal Data Use Certificate (https://adknowledgeportal.synapse.org/DataAccess/DataUseCertificates). https://adknowledgeportal.synapse.org/Explore/Studies/DetailsPage?Study=syn25671134